Potent and selective inhibitor of GSK-3β (IC50=34nM). Stimulates glycogen synthesis in human liver cells and mimics other actions of insulin. Protects primary neurons from death induced by PI-3 kinase pathway inhibition suggesting therapeutic potential in neurodegenerative diseases and stroke. Reduces pulmonary inflammation and fibrosis in a mouse model.
Product Details
| Formula: | C19H12Cl2N2O2 |
| |
| MW: | 371.2 |
| |
| CAS: | 280744-09-4 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Orange solid |
| |
| Solubility: | Soluble in DMSO (>25mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats: M. Kageyama, et al.; PLoS One
14, e0217945 (2019),
Abstract;
Full Text
GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity: A.A. Culbert, et al.; FEBS Lett.
507, 288 (2001),
Abstract;
Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression: P.A. Lochhead, et al.; Diabetes
50, 937 (2001),
Abstract;
Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death: D.A.E. Cross, et al.; J. Neurochem.
77, 94 (2001),
Abstract;
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription: M.P. Coghlan, et al.; Chem. Biol.
7, 793 (2000),
Abstract;
